Clinical trials: in France
Sjogren's Syndrome
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
- Trial name
- NCT04968912
- Testing
- Nipocalimab, Standard of Care Treatment
- Where
- 69 sites in United States, France and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen Research & Development, LLC
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
- Trial name
- NCT07144163
- Testing
- Atumelnant
- Where
- 81 sites in United States, Argentina and 13 more
- Volunteers
- 150 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Obesity, Overweight and/or Obesity
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight
- Trial name
- NCT07595549
- Testing
- PF-08653944
- Where
- 80 sites in United States, Brazil and 9 more
- Volunteers
- 954 people
- Sponsor
- Pfizer
Surgery Ambulatory, ENT Surgery
Feasibility Study of a Conversational Chatbot for Outpatient Postoperative Follow-up in Otorhinolaryngology (ENT): Acceptability, Patterns of Use, and Patient Experience.
Artificial intelligence (AI), and particularly large language models (LLMs), is playing an increasingly important role in medical practice by facilitating documentation, data analysis, and communication with patients.
- Conditions
- Surgery Ambulatory, ENT Surgery, Post Surgical Management
- Trial name
- ORL-CareBOT (NCT07917975)
- Testing
- Post op care
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
- Trial name
- BE MOVING (NCT04436640)
- Testing
- Bimekizumab
- Where
- 75 sites in United States, Belgium and 12 more
- Volunteers
- 508 people
- Sponsor
- UCB Biopharma SRL
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP Substudy 1 (Phase 2) will evaluate efficacy and dose…
- Trial name
- NCT06159673
- Testing
- ACP-204
- Where
- 155 sites in United States, Brazil and 10 more
- Volunteers
- 1,074 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI…
- Trial name
- ECETEP (NCT07766122)
- Testing
- Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Squamous Cell Carcinoma
IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas
Compare patients' feelings in terms of swallowing ability assessed by the overall score of MD Anderson Dysphagia Inventory (MDADI) 2 years after starting treatment between patients who have been treated with IMRT and those who…
- Trial name
- TORPHYNX (NCT04224389)
- Testing
- transoral resection, IMRT
- Where
- 16 sites in France
- Volunteers
- 106 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
ALK-positive NSCLC, ALK-Positive Lung Cancer
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC).
- Conditions
- ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
- Trial name
- NCT07491497
- Testing
- TRI-611
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 160 people
- Sponsor
- TRIANA Biomedicines, Inc.
Triple-Negative Breast Cancer
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with…
- Trial name
- NCT06393374
- Testing
- Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
- Where
- 314 sites in United States, Argentina and 29 more
- Volunteers
- 1,530 people
- Sponsor
- Merck Sharp & Dohme LLC
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study
- Trial name
- OliGRAIL (NCT06840782)
- Testing
- Radical local treatment, SoC-based immunotherapy (+/- chemotherapy)
- Where
- 11 sites in France
- Volunteers
- 124 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Myasthenia Gravis, Generalized
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
The purpose of the HARMONY 360 investigation is to explore the feasibility of using MyoSense 360 digital measures to develop models capable of detecting clinically meaningful changes in generalized Myasthenia Gravis (gMG)…
- Trial name
- HARMONY 360 (NCT07323316)
- Testing
- MyoSense 360
- Where
- 20 sites in Denmark, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Ad scientiam
Metastatic Colorectal Cancer (CRC)
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the…
- Trial name
- HARMONi-GI3 (NCT07228832)
- Testing
- Drug: Ivonescimab Injection, Drug: Bevacizumab Injection
- Where
- 243 sites in United States, Belgium and 13 more
- Volunteers
- 900 people
- Sponsor
- Summit Therapeutics
Falling
Preserving Autonomy Through Foot Health: a Study on the Acceptability of a Program Including Various Workshops for the Elderly
Every year in France, 2 million falls by people over 65 are responsible for 10,000 deaths, the leading cause of accidental death, and more than 130,000 hospitalizations.
- Trial name
- MINIPAS (NCT06421623)
- Testing
- Program Including Various Workshops aiming to preserve elderly's autonomy through foot health
- Where
- 5 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier Emile Roux
Anorexia Nervosa
Speech Groups for Children Living With a Sibling Who Suffers From Anorexia Nervosa
Anorexia nervosa (AN) is a complex mental disease with a huge impact on the patient's siblings life and well-being. Based on literature, group interventions for siblings of children suffering from a chronic disease could provide…
- Trial name
- EMA-FRaM (NCT06528158)
- Testing
- sibling group
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Toulouse
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery.
- Conditions
- Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06324357
- Testing
- Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine
- Where
- 104 sites in United States, Belgium and 8 more
- Volunteers
- 910 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.
- Trial name
- RENEW-Asthma (NCT07219173)
- Testing
- Brenipatide
- Where
- 120 sites in United States, Argentina and 10 more
- Volunteers
- 531 people
- Sponsor
- Eli Lilly and Company
Chronic Kidney Disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.
- Trial name
- NCT07107945
- Testing
- Empagliflozin
- Where
- 93 sites in United States, Argentina and 16 more
- Volunteers
- 135 people
- Sponsor
- Boehringer Ingelheim
Obstructive Sleep Apnea Syndrome
Predictive Factors for Occlusal Changes in Obstructive Sleep Apnea Treatment With Mandibular Advancement Appliance
This research addresses obstructive sleep apnea syndrome (OSAS), affecting 6-12% of French adults, often treated with mandibular advancement devices (MADs).
- Trial name
- APNEAMOUVE (NCT06576310)
- Testing
- Mandibular Advancement Device
- Where
- France
- Volunteers
- 118 people
- Sponsor
- University Hospital, Toulouse
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.